The Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) is a collaborative research network with the overarching goal of discovering molecularly or immunologically targeted agents designed to prevent or intercept the oncogenic process in higher-risk populations. For the purpose of the funding opportunities that will support this discovery research initiative, cancer prevention is defined as primary prevention of cancer before the oncogenic process begins, while cancer interception refers to disruption of the oncogenic process during the precursor or precancer state or stage.
To achieve the program’s goal, CAP-IT research objectives are:
- To identify and functionally validate targets that can be potentially exploited for cancer preventive or interceptive interventions specifically in higher-risk populations, by collaborating with the NCI and other programs with a research focus on molecular profiling of established precursor/precancer, early cancer, and/or oncogenic signaling pathways. The potentially exploitable cancer preventive or interceptive targets include oncogenic molecular targets and pathways, tumor immune microenvironment targets, and tumor-specific/tumor-associated antigens.
- To discover innovative targeted agents through in vitro and in vivo efficacy evaluation and advance promising efficacious agents to the NCI's existing R&D pipeline for further development.
The CAP-IT network will be formed by the U54 Specialized Centers and one U24 Data and Resource Coordination Center.
NCI held a pre-application webinar for the CAP-IT FOAs on August 16th, 2021. Details for the webinar are available in the NIH Guide for Grants and Contracts, NOT-CA-21-097.
The recording of the webinar and answers to submitted questions are posted below for those who were not able to attend.
If you need assistance accessing the pre-application webinar, please contact our Webmaster.